Prediction of pulmonary hypertension in older adults based on vital capacity and systolic pulmonary artery pressure

Simon Wernhart1,2 and Jürgen Hedderich3

Abstract
Objective: Right heart catheterization (RHC) is associated with a higher procedural risk in older adults, but non-invasive estimation of pulmonary hypertension (PH) is a challenge. We aimed to elaborate a non-invasive prediction model to estimate PH.

Methods and design: We retrospectively analysed 134 older adults (70.0 years ±12.3; 44.9% males) who reported to our clinic with unclear dyspnea between 01/2015 and 01/2020 and had received RHC as a part of their diagnostic workup. Lung function testing, analysis of blood gas samples, 6 min walk distance and echocardiography were performed within 24 hours of RHC.

Main outcome measures: In a stepwise statistical approach by using an in/exclusion algorithm (using the AIC criterion) we analysed non-invasive parameters to test their value in predicting PH (defined as mean pulmonary artery pressure, PAmean, >25mmHg). Discrimination capability of the final model was measured by the AUC (area under curve) from an ROC (receiver operating characteristics) analysis.

Results: We yielded a sensitivity of 87.2% and a specificity of 62.5% in a combinatorial logistical model with systolic pulmonary artery pressure (sPAP) and forced vital capacity (VCmax), the discrimination index was 86.7%. The odds ratios for an increase of 10 mmHg of sPAP were 2.99 (2.08–4.65) and 1.86 (1.11–3.21) for a 1 l decrease in VCmax. On their own, VCmax proved to be specific (83.3%), while sPAP was a sensitive (79.1%) predictor for PH.

Conclusions: We provide a combinatorial model to predict PH from sPAP and VCmax in older adults, which may help to avoid invasive procedures.

Keywords
Risk assessment, pulmonary circulation, echocardiography, vital capacity, avoiding invasive procedures

Date received: 5 October 2020; accepted: 25 October 2020

Introduction
Elucidating the etiology of dyspnea in multimorbid patients can be challenging and often requires cardiological, pneumological, rheumatological, infectious or endocrinological investigations. A crucial factor for diagnosis is pulmonary hypertension, PH, given its high correlation with both morbidity and mortality.1 The current ESC guidelines differentiate between isolated pre- and post-capillary PH as well as combined pre- and post-capillary PH, CpcPH.3 Non invasive parameters of mortality risk stratification in pulmonary arterial hypertension (PAH) and PH have been established and have been validated in other cohorts.3,4 Recently, hypochloremia has been suggested as a non-invasive marker to predict one, three- and five-year-survival in PH.5

1Department of Cardiology, Fachkrankenhaus Kloster Grafschaft, Schmallenberg, Germany
2West German Heart- and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany
3Medistat-Biomedical Statistics, Medistat GmbH, Kronshagen, Germany

Corresponding author:
Simon Wernhart, West German Heart- and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, Hufelandstr.55, 45147 Essen, Germany. Email: simon.wernhart@gmx.de

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/creativecommons-at-sage).
However, definitive diagnosis demands right heart catheterization (RHC), which is an invasive method with associated risks. Especially in older adults invasive investigations are often complicated and sometimes not feasible. Echocardiography studies have provided an array of parameters and indices to non-invasively predict P(A)H and outcome.\(^6\)\(^-\)\(^10\) FEV\(_1\) (forced expiratory volume in one second), exercise induced desaturation and 6 MWD (6 minute walk distance), carbon monoxide transfer coefficient (KCO) and carbon monoxide diffusing capacity of the lung (DLCO) have been associated with echocardiographic systolic pulmonary artery pressure (sPAP) in univariate analysis.\(^11\)\(^,\)\(^12\)

Additionally, cardiopulmonary exercise testing (CPET) seems to contribute to the prognostic values of 6 MWD in predicting survival in PH.\(^13\)

In summary, a considerable number of single non-invasive variables have been suggested as surrogates for predicting or estimating PH, but none are sufficiently robust for clinical use on their own. This may be due to high interdependence between the variables due to the complex pathophysiology of PH.

Developing an easily applicable prediction model for PH is of utmost clinical importance, since diagnosis of PH is often prolonged, with deleterious consequences, including mortality, in patients with chronic heart failure. To fill this gap we developed a stepwise statistical approach to elucidate a model consisting of non-invasive variables to estimate PH probability with minimal interdependence of variables. Our aim is to provide a non-invasive tool for clinicians to quickly estimate PH probability in older adults in daily practice.

**Methods**

We retrospectively analyzed 134 older adults admitted to our clinic between 01/2015 and 01/2020 for clinical evaluation and differential diagnosis of dyspnea, all of whom received right heart catheterization as a part of their differential diagnostic workup during hospital stay. The indication for RHC was stated when the reason for dyspnea was not discovered with non-invasive measures. Older adults were defined as being 70 years of age or older or at least 55 years with clinically significant cardiopulmonary limitations (at least NYHA II). Prior to RHC, presence of, or progression of previously diagnosed coronary artery disease had to be excluded invasively or non-invasively. In case of clinical and echocardiographic congestion at hospital admission, patients were treated with intravenous-diuretics and RHC was performed at a clinically recompensated state. Patients had provided written consent to anonymous data usage at hospital admission. In the presence of unclear dyspnea with the need for further medical check-up, there were no exclusion criteria to the study. We collected baseline characteristics (Tables 1 and 2) of our patients, including available blood chemistry, LFT, echocardiography, 6 MWD, and blood gas analysis.

We established a clinically oriented priority list of non-invasive independent variables for further univariate analysis with the dependent variable mean pulmonary artery pressure (PA\(_{\text{mean}}\)):

- Sex, age, hypertension, coronary artery disease, valvular dysfunction (defined as at least grade II stenosis or insufficiency on trans-thoracic echocardiography), left ventricular ejection fraction (LVEF: separation via eyeballing into normal, >50%, moderately reduced, 40–50%, and highly reduced, <40%), right ventricular ejection fraction, RVEF [normal: TAPSE (tricuspid annular plane systolic excursion) >15mm, and considerably reduced <10mm], systolic pulmonary artery pressure (sPAP) and oxygen content in capillary blood at rest, \(c_{\text{O}_2}\)

| Table 1. Baseline characteristics. |
|-----------------------------------|
| **Age** | 70.0 years ± 12.3 |
| **Weight** | 83.48 kg ± 17.5 |
| **BMI** | 28.9 kg/m\(^2\) ± 5.6 |
| **Males** | 44.9% |
| **Hypertension** | 80.5% |
| **Diabetes** | 21.6%, 9.7% on insulin |
| **Smokers** | 24.6% |
| **Coronary artery disease** | 31.3% |
| **Cardiomyopathy** | 28.4% |
| **Atrial fibrillation** | 41.8% |
| **Oral anticoagulation** | 54.5% |
| **Chronic obstructive pulmonary disease** | 27.8% |
| **Restrictive pulmonary disease** | 11.0% |
| **History of myocardial infarction** | 9.7% |
| **History of CABG** | 8.3% |
| **History of stroke** | 7.5% |
| **Hemoglobin** | 13.8 g/dl ± 1.9 |
| **GFR** | 67.4 ml/min ± 23.0 |
| **LDL cholesterol** | 103.1 mg/dl ± 42.3 |
| **LTOT** | 22.9% |
| **CPAP** | 12.3% |
| **NIV** | 9.1% |
| **ACE / ARBs** | 71.4% |
| **CCB** | 30.8% |
| **Beta-blockers** | 72.2% |
| **Diuretics** | 81.1% |

Baseline characteristics, mean values and standard deviations are listed where appropriate (\(n = 134\)). Chronic obstructive pulmonary disease was defined as a Tiffeneau index < 70%. Relevant restrictive lung disease was defined as a \(V_{\text{Cmax}}\) < 85%. CABG: coronary artery bypass grafting; GFR: glomerular filtration rate calculated by MDRD-formula; LTOT: long-term oxygen treatment; CPAP: continuous positive airway pressure ventilation; NIV: non-invasive, bilevel, ventilation; ACE/ARBs: angiotensin converting enzyme/angiotensin receptor blockers; CCB: calcium channel blockers.
Echocardiographic findings and lung function testing. Mean values and standard deviations are shown where appropriate. LVEF: left ventricular ejection fraction, defined with eyeballing by an experienced echocardiographer; RVEF: right ventricular ejection fraction, defined by TAPSE; TAPSE: tricuspid annular plane systolic excursion; VCmax: vital capacity; FEV1: forced expiratory ventilation in 1 s; RV: residual volume; RV/TLC: residual volume/total lung capacity; KCO: transfer coefficient of the lung for carbon monoxide, CO (n = 134).

Table 2. Characteristics of echocardiography and lung function testing.

| LVEF (EF > 50%) | 75.9% |
|----------------|-------|
| Midrange reduced LVEF (40–50%) | 3.0% |
| Considerably reduced LVEF (<40%) | 21.1% |
| Preserved RVEF (TAPSE >15mm) | 76.0% |
| Considerable reduction of RVEF (TAPSE <10 mm) | 16.5% |
| Relevant valvular dysfunction (≥grade II) | 38.5% |
| VCmax | 2.6l ± 1.0 |
| FEV1 | 1.9l ± 0.8 |
| RV | 3.0l ± 1.4 |
| RV/TLC | 122.9%±36.3 |
| KCO | 69.4%±27.6 |

The predictive capabilities of the final model were visualized in a nomogram.

Results

Our patients showed a plethora of cardiovascular risk factors with 80.5% hypertensives, 21.6% diabetics and 24.6% smokers. Cardiomyopathies and coronary artery disease were present in 50%. Almost half of our patients suffered from atrial fibrillation and one third showed relevant valvular disorders (38.5%), which, together with the high amount of hypertensives, the mainly preserved LVEF (75.9%) and RVEF (76.0%) would suggest more cases of post-capillary PH of all PH patients (64.9% overall). However, the majority showed a combination of pre- and post-capillary PH (CpPH, 40.2%; 36.8% isolated pre-capillary, 23.0% isolated post-capillary), mainly with preserved cardiac output (mean cardiac index 2.31/min/m²). Heart failure medication had been established in most cases. Additionally, lung disease, either obstructive or restrictive, had been diagnosed in one third of patients, 22.9% had an established long-term oxygen supply (cumulative data from RHC are provided in Table 3).

Univariate analysis

Univariate analysis of the independent variables and PAmean revealed that 6 MWD (r = −0.33), FEV1 (r = −0.34), VCmax (r = −0.32), valvular dysfunction (p < .001), TAPSE (p < .001), sPAP (r = 0.58) and oxygen content (r = −0.25) should be more closely analyzed in a prediction model. Arterial hypertension (p = 0.751), coronary artery disease (p = 0.397) and LVEF (p = 0.863) did not show any differences and were not included in the following regression analysis.
Sex (p = 0.596) and age (r = 0.40) as potential confounders were considered (Table 1a and b of supplement 2).

Logistic multivariable regression model

Initially, non-parametric correlations were calculated and displayed considerable correlations between PAmean, sPAP (r = 0.58; p < .001), oxygen content (r = −0.25; p < .001), 6 MWD (r = −0.33; p < .001), VCmax (r = −0.31; p < .001) and FEV1 (r = −0.33; p < .001, see Figure 1 in supplement 3). This, however, signifies that inclusion of all parameters in the model is not warranted due to interdependence of the parameters. The variables alone differed significantly between PAmean above and below 25 mmHg, but would produce a systematic error in a regression model.

For a full and plausible logistic regression model a clinical decision on restriction of variables had to be made. We chose to include sPAP, VCmax, FEV1, 6 MWD, RVEF-TAPSE, valve dysfunction, oxygen content, sex and age. Significance was yielded for sPAP (< .001) and VCmax (p = .021), but not for 6 MWD (p = .276), FEV1 (p = .222), RVEF-TAPSE (p = .399), valve dysfunction (p = .230), oxygen content (p = .810), age (p = .128) and sex (p = .127; for full regression data see Table 2a in supplement 2). After stepwise forward/backward modeling (AIC analysis), VCmax and sPAP remained for further analysis. Thus, a reduced model was calculated with sPAP and VCmax as well as sex and age, the latter two did not play a significant role and were omitted in the final model (for regression data see Table 2b in supplement 2).

Regression coefficients were converted to Odds Ratio (OR): the OR for a 10 mmHg increase in sPAP was 2.99 (95% CI: 2.08–4.65) and 1.86 for a 1 l decrease in VCmax (95% CI: 1.11–3.21).

Separate univariate ROC analysis yielded an estimated specificity for sPAP of 81.3% (70.8% to 91.7%) and sensitivity was 79.1% (69.8% to 87.2%). The estimated specificity for VCmax was 83.3% (72.9% to 93.8%) and sensitivity was 46.5% (36.1% to 57.0%).

In the final multivariable logistic regression model sPAP and VCmax discriminated well in terms of the presence of PH (discrimination index 86.7%, AUC 0.8665, Figure 1). Sensitivity was 87.2% and specificity 62.5% at a cut-off value of 0.5.

Discussion

We assessed non-invasive risk predictors for pulmonary hypertension in a population of older patients reporting for differential diagnosis of unclear dyspnea. With a mean age of 70.5 years our patients represent a multi-morbid population.

We systematically analyzed both pneumological and cardiological factors in terms of their value for a prediction model for PH. The complexity of PH was demonstrated through multiple interactions between the potential independent variables, which forced us to set clinical priorities for the model (Table 2 of supplement 2). For instance, FEV1, oxygen content, TAPSE and 6 MWD differed significantly between patients with and without PH and may provide clues to suspect PH in patients with dyspnea (Figures see supplement 3), but inclusion in the model was not useful due to their interaction potential. The problem of multiple variables has
already been addressed in the literature and careful selection of parameters has been suggested.\textsuperscript{16}

We used a stepwise approach to filter the most suitable factors, which left sPAP and VC\textsubscript{max} as the most predictive factors. Recently, Lurz et al. analyzed the role of PH in severe tricuspid regurgitation and its implications for transcatheter tricuspid valve repair (TVVR) with the MitralClip\textsuperscript{TM} technique in 243 patients.\textsuperscript{17} They found that the diagnostic accuracy of echocardiography to detect an invasive systolic PA pressure $>$50 mmHg was only 55\% in their population,\textsuperscript{17} which suggests that sPAP alone has insufficient diagnostic value for PH detection. Using our model by adding VC\textsubscript{max} may achieve a higher diagnostic yield. In the logistic model especially sPAP displayed a sinusoid relationship in terms of probability for PA\textsubscript{mean} $>$25 mmHg, while VC\textsubscript{max} had a curvilinear course (Figure 2). The figure illustrates that an sPAP increase boosts the probability of PH between 30 to 50 mmHg—the corridor in which clinical decision-making is often problematic. The interpretation of the significance of an sPAP in this range, in terms of the presence of PH, can be difficult.

In our combined (sPAP and VC\textsubscript{max}) logistic model we yielded a sensitivity of 87.2\% and specificity of 62.5\%. This produced a benefit in sensitivity compared to a separate analysis of the factors (sPAP: 79.1\% and VC\textsubscript{max} 46.5\%), but at the expense of specificity (sPAP 81.3\%; VC\textsubscript{max} 83.3\%). A discrimination index of 86.7\% of the combined model (see Figure 2) is relevant for clinical purposes. Moreover, the complementary nature of the two variables (VC\textsubscript{max} as a specific factor and sPAP as a sensitive marker) can be integrated into clinical practice. Patients with low sPAP in echo

![Figure 2](image-url). Estimated probability (x-axis) for PA\textsubscript{mean} (mean pulmonary artery pressure) $>$25 mmHg from the logistic model for sPAP (systolic pulmonary artery pressure) and VC\textsubscript{max} (maximal vital capacity). The y-axis shows sPAP [mmHg] on the left and VC\textsubscript{max} [l] on the right (n = 134).

![Figure 3](image-url). Nomogram with evaluation of the independent variables on a linear scale (total points given). The points reflect the probability of PA\textsubscript{mean} (mean pulmonary artery pressure) $>$25 mmHg.
but clinical symptoms compatible with PH need to be further investigated. VC\textsubscript{max} can provide additional, valuable information on risk stratification (see nomogram, Figure 3). We are aware that VC\textsubscript{max} is dependent on age and fluid status (congestion may reduce VC\textsubscript{max} temporarily). However, in our study fluid status has not been a confounder since we only perform RHC (apart from the intensive care unit) after recompensation with diuretics. A single measurement of VC\textsubscript{max} may not be sufficient to give the diagnosis PH. However, over time, relative changes of VC\textsubscript{max} in a patient could provide clinicians with valuable information on increasing risk of PH and may guide clinical decision making on escalating medical therapy.

In the nomogram an sPAP of 40 mmHg (three points) and a VC\textsubscript{max} of 41 (one point) cumulates in a PH probability of around 37% (a total of four points), while a VC\textsubscript{max} of 11 (2.5 points) with the same sPAP leads to a probability of 75% (5.5 points)! Thus, VC\textsubscript{max} is an important discriminator of PH likelihood in the sPAP grey zone of 30–50 mmHg. VC\textsubscript{max} is suitable for a prediction model, because it also integrates the dimensions age and body surface.

Correale et al., 2019 have implemented a scoring system to predict PH entirely through echocardiographic factors in a small population of cardiological patients (n = 64) and yielded similar sensitivity and specificity (93 and 67%, AUC 0.786) compared to our model.\textsuperscript{18} They suggested right atrial and ventricular diastolic area, maximal velocity of tricuspid regurgitation and left ventricular ejection fraction as variables. However, the right ventricle is often difficult to visualize and measure, especially in concomitant pulmonary disease with dynamic hyperinflation. In our study right ventricular function, expressed by TAPSE, was not a suitable prediction factor of PH. We are aware that TAPSE only measures annular plane excursion and has limited validity in regional wall motion abnormalities, but nevertheless seems to be a predictor of major cardiovascular events in patients with stable coronary artery disease.\textsuperscript{19} TAPSE is often easily measurable and does not take much time in clinical routine. The value of RV dysfunction as a factor to predict mortality is well-established.\textsuperscript{20} Therefore integration of geometric and dynamic parameters of RV function, such as right ventricular and atrial strain, may also add information to a PH prediction model. RV-peak systolic strain rate, for instance, was recently shown to predict peak oxygen consumption in patients with group I PH (AUC = 0.88) and may also be used as a variable in future models for others than PH group 1.\textsuperscript{21}

The ratio of TAPSE/sPAP as a marker of RV/PC coupling (right ventricular-pulmonary circulation), which has shown predictive quality in hospitalization frequency in heart failure patients,\textsuperscript{22,23} could also be used in a future prediction model of PH. Guazzi et al., 2015 used EOV (exercise oscillatory ventilation) during CPET and TAPSE/sPAP to predict major cardiac events.\textsuperscript{23} However, CPET is not always applicable in daily clinical routine, contrary to LFT (and VC\textsubscript{max}).

Additionally, LVEF did not prove to be a predictor of PH, which emphasizes that there may be other parameters, such as the unspecific BNP or the more subtle parameter left ventricular strain, to express (left) cardiac stress. Evidence exists that enhanced BNP is a marker of the presence of CpcPH in patients with severe aortic stenosis.\textsuperscript{24}

LFT parameters and PH prediction have also been reported in the literature. An interesting study of 105 patients with idiopathic pulmonary fibrosis (IPF) revealed that the ratios FVC/DLCO (forced vital capacity/diffusion capacity) and diameters of pulmonary artery/aorta were useful adjuncts to sPAP to predict PH in a linear regression model (R\textsuperscript{2} = 0.39).\textsuperscript{25} Another small study (n = 61) with IPF patients regressed FVC/DLCO and resting pulse oximetry with PA\textsubscript{mean} as a continuous variable (R\textsuperscript{2} = 0.55).\textsuperscript{26} Whether these models are reliable in cardiological patients without lung disease is unclear.

Our study population adds valuable information to the literature because it consisted of typical multimorbidity, older patients of internal medicine with a high coincidence of cardiological and pulmonary diseases, a group often excluded in clinical trials. In these patients PH diagnosis is usually difficult, because symptom progression can be subtle and early risk assessment is of paramount importance.\textsuperscript{27–29} In such a population integration of parameters of LFT and echo seems reasonable. Integration of a greater number of variables into a prediction model of PH does not facilitate prediction due to the high interdependence of the factors. Our approach systematically reduced the number of factors necessary to elaborate a powerful model with complementary factors, which can be incorporated into clinical practice.

Thus, our study provides an important tool for personalized stratification to detect PH in older adults without invasive procedures. We provide a clinically applicable model for physicians treating older adults to estimate PH probability and reduce the number of invasive procedures, such as RHC, which have a higher peri-procedural risk and put older patients under a lot of stress. This would apply to situations, in which a low risk score for PH is calculated. However, in case of a high probability for PH invasive diagnostics will still be necessary (despite higher procedural risks) to discriminate the etiologies of PH and choose the appropriate treatment options.
Limitations

There are limitations to our study. Methodological limitations due to the retrospective nature of the study and the limited sample size have to be acknowledged. Although, we provided internal validation of our model, the scoring system has to be validated in larger cohorts. Our population consisted of multimorbid but still mobile (mean 6 MWD 321 m) patients with a high percentage of pulmonary co-morbidities, bearing the risk of selection bias. The common denominator of our patients was dyspnea, 64.9% of which had PH as a diagnosis. Additionally, our model does not allow a statement on the etiology of PH. Larger populations with different clinical profiles and pre-test probabilities for PH would be necessary to validate our clinically appealing approach. Additionally, NTproBNP values were not completely available and had no predictive power in our model.

Conclusion

In summary, we elaborated an easily applicable model of non-invasive parameters as predictors of pulmonary hypertension in older adults. VC\textsubscript{max} and sPAP provided a valuable complementary model particularly useful in the group with lower sPAP in echo. Our model helps to stratify the probability of PH in elderly, multimorbid patients. This easily applicable model could be used as a standard in cardiopulmonary practice to predict PH in older adults and help to further reduce unnecessary invasive procedures in older patients without missing treatment options.

Data availability

Supplementary analyses and data will be made available by the corresponding author on reasonable request.

Acknowledgements

The authors thank Prof. Eberhard Weihe, MD, from the Institute of Anatomy and Cell Biology of the Philipps-University Marburg, Germany, for valuable comments and suggestions on the manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

The study complies with the Declaration of Helsinki. Written informed consent has been obtained from the participants or their legal representatives. After consultation of the local ethics committee (University Münster, Germany) a direct vote of the committee was not necessary due to the retrospective nature of the study and analysis of our own institutional data.

Guarantor

The corresponding author is responsible for the validity and discretion of data analysis.

Contributorship

Both authors contributed to the design and compilation of the study. SW wrote the manuscript, JH did the statistics.

ORCID iD

Simon Wernhart https://orcid.org/0000-0001-6732-0939

Supplemental Material

Supplementary material for this article is available online.

References

1. Mullin CJ, Khair RM, Damico RL, et al. Validation of the REVEAL prognostic equation and risk score calculator in incident systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheumatol 2019; 71: 1691–1700.
2. “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS).” Simon Gibbs, Irene Lang, Adam Torbicki, Gerald Simonneau, Andrew Peacock, Anton Vonk Noordgraaf, Maurice Beghetti, Ardeschir Ghofrani, Miguel Angel Gomez Sanchez, Georg Hansmann, Walter Klepetko, Patrizio Lancellotti, Marco Matteucci, Theresa McDonagh, Luc A. Pierard, Pedro T. Trindade, Maurizio Zompatori and Marius Hoeper. Eur respir J 2015; 46: 903-975. Eur Respir J 2015; 46: 1855–1856.
3. Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740–1700705.
4. Sitbon O, Benza RL, Badesch DB, et al. Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J 2015; 46: 152–164.
5. Prins KW, Kalra R, Rose L, et al. Hypochloremia is a noninvasive predictor of mortality in pulmonary arterial hypertension. J Am Heart Assoc 2020; 9: e015221.
6. Amsallem M, Sweat AJ, Aymami MC, et al. Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension: comparison with
validated models. Circ Cardiovasc Imaging 2017; 10: e005771.

7. Guo X, Lai J, Wang H, et al. Predictive value of non-invasive right ventricle to pulmonary circulation coupling in systemic lupus erythematosus patients with pulmonary arterial hypertension. Eur Heart J Cardiovasc Imaging. Epub ahead of print 25 December 2019. doi: 10.1093/ehjci/jez311.

8. Kusunose K, Yamada H, Hotchi J, et al. Prediction of future overt pulmonary hypertension by 6-min walk stress echocardiography in patients with connective tissue disease. J Am Coll Cardiol 2015; 66: 376–384.

9. Richter SE, Roberts KE, Preston IR, et al. A simple derived prediction score for the identification of an elevated pulmonary artery wedge pressure using precatheterization clinical data in patients referred to a pulmonary hypertension center. Int J Cardiovasc Imaging 2019; 35: 861–868.

10. Ran H, Schneider M, Pistritto AM, et al. Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertension. Int J Cardiovasc Imaging 2019; 35: 861–868.

11. Gartman EJ, Blundin M, Klinger JR, et al. Initial risk assessment for pulmonary hypertension in patients with COPD. Lung 2012; 190: 83–89.

12. Higham MA, Dawson D, Joshi J, et al. Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD. Eur Respir J 2001; 17: 350–355.

13. Groepenhoff H, Vonk-Noordegraaf A, Boonstra A, et al. Exercise testing to estimate survival in pulmonary hypertension. Med Sci Sports Exerc 2008; 40: 1725–1732.

14. Harrell FE. rms: Regression Modeling Strategies. R package version 5.1-4, https://CRAN.R-project.org/package=rms (2019, accessed 20 September 2020).

15. Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing, https://www.R-project.org/ (2020, accessed 20 September 2020).

16. Cogswell R, Pritzker M and De Marco T. Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters. J Heart Lung Transplant 2014; 33: 382–387.

17. Lurz P, Orban M, Besler C, et al. Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair. Eur Heart J. Epub ahead of print 3 March 2020.

18. Correale M, Tricarico L, Padovano G, et al. Echocardiographic score for prediction of pulmonary hypertension at catheterization: the Daunia heart failure registry. J Cardiovasc Med (Hagerstown) 2019; 20: 809–815.

19. Giovanardi P, Tincani E, Maioli M, et al. The prognostic importance of TAPSE in early and in stable cardiovascular diseases. J Cardiovasc Dev Dis 2020; 7. DOI: 10.3390/jcdd7010004.

20. Padang R, Chandrashekar N, Indrabhinduwat M, et al. Aetiology and outcomes of severe right ventricular dysfunction. Eur Heart J 2020; 41: 1273–1282.

21. Liu BY, Wu WC, Zeng QX, et al. Two-dimensional speckle tracking echocardiography assessed right ventricular function and exercise capacity in pre-capillary pulmonary hypertension. Int J Cardiovasc Imaging 2019; 35: 1499–1508.

22. Guazzi M, Dixon D, Labate V, et al. RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging 2017; 10: 1211–1221.

23. Guazzi M, Naeije R, Arena R, et al. Echocardiography of right ventriculoarterial coupling combined with cardiopulmonary exercise testing to predict outcome in heart failure. Chest 2015; 148: 226–234.

24. Maeder MT, Weber L, Ammann P, et al. Relationship between B-type natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis. ESC Heart Fail. Epub ahead of print 30 January 2020. DOI: 10.1002/ehf2.12614.

25. Sonti R, Gersten RA, Barnett S, et al. Multimodal non-invasive prediction of pulmonary hypertension in IPF. Clin Respir J 2019; 13: 567–573.

26. Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101: 2153–2159.

27. Lang IM and Palazzini M. The burden of comorbidities in pulmonary arterial hypertension. Eur Heart J Suppl 2019; 21: K21–K28.

28. McLaughlin VV, Hoepfer MM, Channick RN, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol 2018; 71: 752–763.

29. Sitbon O, Chin KM, Channick RN, et al. Risk assessment in pulmonary arterial hypertension: insights from the GRIPHON study. J Heart Lung Transplant 2020; 39: 300–309.